Srs Capital Advisors, Inc. Supernus Pharmaceuticals, Inc. Transaction History
Srs Capital Advisors, Inc.
- $977 Million
- Q2 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Supernus Pharmaceuticals, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 139 shares of SUPN stock, worth $4,461. This represents 0.0% of its overall portfolio holdings.
Number of Shares
139
Previous 35
297.14%
Holding current value
$4,461
Previous $1,000
200.0%
% of portfolio
0.0%
Previous 0.0%
Shares
5 transactions
Others Institutions Holding SUPN
# of Institutions
255Shares Held
59.2MCall Options Held
47.9KPut Options Held
13.1K-
Black Rock Inc. New York, NY10.4MShares$334 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.14MShares$197 Million0.0% of portfolio
-
Armistice Capital, LLC New York, NY5.27MShares$169 Million1.83% of portfolio
-
Dimensional Fund Advisors LP Austin, TX2.87MShares$92 Million0.02% of portfolio
-
Macquarie Group LTD Australia, C32.68MShares$86 Million0.08% of portfolio
About SUPERNUS PHARMACEUTICALS, INC.
- Ticker SUPN
- Exchange NASDAQ
- Sector Healthcare
- Industry Drug Manufacturers—Specialty & Generic
- Shares Outstandng 53,495,300
- Market Cap $1.72B
- Description
- Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. Its commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prop...